Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | ACP3 | P15309 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | LDHB | P07195 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10465540 | 0.84 | GSK3B (0.59) | GSK3BACP3PDPK1CES2CES1 | |
| SCHEMBL9280969 | 0.82 | GSK3B (0.52) | GSK3BACP3PDPK1CES2CES1 | |
| SCHEMBL839084 | 0.82 | CES2 (0.53) | GSK3BACP3PDPK1CES2CES1 | |
| SCHEMBL3107743 | 0.80 | GSK3B (0.64) | GSK3BACP3PDPK1CES2CES1 | |
| SCHEMBL3312220 | 0.80 | CES2 (0.47) | PDPK1CES2AKR1C3AKR1C2 | |
| SCHEMBL2657735 | 0.80 | NR1H4 (0.47) | CES2CES1SRD5A2AKR1C3AKR1C2 | |
| SCHEMBL7436009 | 0.79 | CES2 (0.55) | ACP3CES2SRD5A2AKR1C3AKR1C2 | |
| SCHEMBL30015679 | 0.79 | CES2 (0.55) | ACP3CES2SRD5A2AKR1C3AKR1C2 | |
| SCHEMBL3130953 | 0.79 | CES2 (0.53) | GSK3BACP3PDPK1CES2CES1 | |
| SCHEMBL9047892 | 0.79 | SRC (0.54) | GSK3BACP3PDPK1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023155873-A1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF IN PHARMACEUTICS | 江苏恒瑞医药股份有限公司 | 2023-08-24 | — | — | WO | disclosed |
| EP-3197900-B1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME (US) | 2020-02-12 | — | — | EP | disclosed |
| US-9969752-B2 | Inhibitors of HIF prolyl hydroxylase | MERCK SHARP & DOHME CORP. (US) | 2018-05-15 | — | — | US | disclosed |
| CN-104395324-B | Mi Zuo Bing oxadiazoles and imidazo thiadiazoles derivative | 阿瑞斯贸易股份有限公司 | 2017-09-12 | — | — | CN | disclosed |
| US-20170233412-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-17 | — | — | US | disclosed |
| EP-3197900-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | Merck Sharp & Dohme Corp. (US) | 2017-08-02 | — | — | EP | disclosed |
| CN-106986832-A | Vegfr3 inhibitor | 癌症治疗合作研究中心有限公司 | 2017-07-28 | — | — | CN | disclosed |
| WO-2016049099-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| EP-0482080-B1 | SMALL CYCLIC PLATELET AGGREGATION INHIBITORS | GENENTECH INC (US) | 1997-03-26 | — | — | EP | disclosed |
| EP-0555328-A1 | PLATELET AGGREGATION INHIBITORS | GENENTECH, INC. (US) | 1993-08-18 | — | — | EP | disclosed |
| WO-1992007870-A1 | PLATELET AGGREGATION INHIBITORS | GENENTECH, INC. (US) | 1992-05-14 | — | — | WO | disclosed |
| US-4307232-A | Preparation of dialkyl- and diarylphosphonoalkanoic acids and substituted acrylic acids | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | GSK3B 283/4885ACP3 1554/4885PDPK1 443/4885 |
| US-20170233412-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | GSK3B 1132/4885ACP3 905/4885PDPK1 1038/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | GSK3B 294/4885ACP3 1144/4885PDPK1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.